Nachrichten zur AcelRx Pharmaceuticals Aktie

AcelRx Pharmaceuticals to Participate in Two September Investor Conferences

HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the…

AcelRx touts benefit of Dsuvia for pain following outpatient plastic surgery

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about buying stock in NanoVibronix, Advanced Micro Devices, Romeo Power, Futu Holdings, or AcelRx Pharmaceuticals?

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAOV, AMD, RMO, FUTU, and ACRX. To…

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do…

AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results

HAYWARD, Calif., Aug. 16, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the…

AcelRx Pharmaceuticals Q2 2021 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx…

AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021

HAYWARD, Calif., Aug. 9, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx…

ACELRX PHARMACEUTICALS INC: 8-K Report

FORM 8-K...…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx…

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ACRX

NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)

LOS ANGELES, July 23, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 9,…

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors

LOS ANGELES, July 21, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx…

AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United…

ACELRX PHARMACEUTICALS INC: 8-K Report

FORM 8-K...…

AcelRx Pharmaceuticals, GBS leads healthcare gainers; Allied Healthcare Products, Allena Pharmaceuticals among

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AcelRx, Aguettant Ink Licensing Agreements For Dzuveo And Two Prefilled Syringe Products

AcelRx inks multiple licensing agreements with Aguettant

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S.

HAYWARD, Calif., July 14, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the…

ROSEN, A TOP RANKED FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX

NEW YORK, July 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)

BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming August 9,…

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors

LOS ANGELES, June 25, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit…

ACELRX PHARMACEUTICALS INC: 8-K Report

FORM 8-K...…

Bionano Genomics to join Russel 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX

NEW YORK, June 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing…

ACRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

NEW YORK, June 10, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class…

Pomerantz Law Firm Announces the Filing of a Class Action Against AcelRx Pharmaceuticals, Inc. and Certain Officers - ACRX

NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx…

AcelRx launches Dsuvia study in sickle cell disease presenting to the emergency department

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease

HAYWARD, Calif., May 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the…